GCM
ABBV icon

Genus Capital Management’s AbbVie ABBV Stock Holding History

Genus Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-38,785
Closed -$6.89M – 184
2024
Q4 		$6.89M Sell
38,785
-21,264
-35% -$3.91M 0.94% 30
2024
Q3 		$11.9M Buy
60,049
+25,519
+74% +$4.76M 1.55% 16
2024
Q2 		$5.92M Buy
+34,530
New +$5.72M 0.78% 46

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Genus Capital Management's ABBV Position: Q2 2026 in Review

Genus Capital Management increased its AbbVie (ABBV) stake by 662% in Q2 2026, buying an estimated $4.98M and bringing the position to 26,668 shares worth $6.71M. The position accounts for 0.66% of the portfolio, ranked #48.

Genus Capital Management first reported a position in ABBV in Q1 2024 and has held it in 7 quarters since. The position peaked at $14.5M in Q4 2025. 4,227 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Genus Capital Management held 26,668 shares of AbbVie worth $6.71M as of Q2 2026.
  • Genus Capital Management bought 23,170 AbbVie shares in Q2 2026, an estimated $4.98M.
  • AbbVie made up 0.66% of Genus Capital Management's portfolio in Q2 2026, its #48 holding.
  • Genus Capital Management first reported a position in AbbVie in Q1 2024 and has held it in 7 quarters since.
  • Genus Capital Management's AbbVie position peaked at $14.5M in Q4 2025.
  • 4,227 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Genus Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.